The three agents demonstrate synergistic effects in antitumor activity and immune regulation, which may make the combination of thalidomide, rhIFNα-1b, and IL-2 a novel effective therapeutic regimen for AML. The gene discussed is IL2; the disease is acute myeloid leukemia.